Proceedings of the 2023 3rd International Conference on Business Administration and Data Science (BADS 2023)

<Previous Article In Volume
Next Article In Volume>

Whether the public procurement policy can increase R&D innovation in the pharmaceutical enterprises

Authors
Jianqun Wu1, *
1Business School, Sichuan University, Chengdu, China
*Corresponding author. Email: 1693467529@qq.com
Corresponding Author
Jianqun Wu
Available Online 30 December 2023.
DOI
10.2991/978-94-6463-326-9_6How to use a DOI?
Keywords
Public procurement policy; Pharmaceutical enterprises; R&D investment; Regression discontinuity design
Abstract

In November 2018, with the implementation of drug quantity Purchase in ‘4 + 7’ pilot cities, China‘s drug purchase system stepped into a new level. With the continuous advancement of China‘s drug public procurement policy, the situation of the pharmaceutical industry has changed tremendously. The days when companies rely on generic drugs to obtain high profits are gone, and innovation has become the only way for pharmaceutical companies to develop. By selecting the data of listed companies in the pharmaceutical industry from 2015 to 2021 as a sample, this paper uses the SRD to study the correlation between the drug public procurement policy and the R&D innovation of the pharmaceutical enterprises. And the empirical result shows that the public procurement policy has a positive effect on them, and it is still established after a series of robustness tests. Based on the results, we put forward some policy recommendations.

Copyright
© 2023 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

<Previous Article In Volume
Next Article In Volume>
Volume Title
Proceedings of the 2023 3rd International Conference on Business Administration and Data Science (BADS 2023)
Series
Atlantis Highlights in Computer Sciences
Publication Date
30 December 2023
ISBN
10.2991/978-94-6463-326-9_6
ISSN
2589-4900
DOI
10.2991/978-94-6463-326-9_6How to use a DOI?
Copyright
© 2023 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Cite this article

risenwbib
TY  - CONF
AU  - Jianqun Wu
PY  - 2023
DA  - 2023/12/30
TI  - Whether the public procurement policy can increase R&D innovation in the pharmaceutical enterprises
BT  - Proceedings of the 2023 3rd International Conference on Business Administration and Data Science (BADS 2023)
PB  - Atlantis Press
SP  - 51
EP  - 60
SN  - 2589-4900
UR  - https://doi.org/10.2991/978-94-6463-326-9_6
DO  - 10.2991/978-94-6463-326-9_6
ID  - Wu2023
ER  -